Targeting bicarbonate transport as a “first-in-class” therapeutic strategy to promote CD8+ T cell fitness and enhance cancer immunotherapy

This project aims to develop and commercialize bicarbonate transporter blockers to enhance CD8+ T cell efficacy and improve immunotherapy outcomes in pancreatic cancer.

Subsidie
€ 150.000
2022

Projectdetails

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancer types. It is virtually resistant to any sort of therapy, including the most recent immunotherapies.

Tumor Microenvironment

These tumors are characterized by a strong hypoxic, nutrient-poor, and acidic tumor microenvironment (TME), in which cytotoxic CD8+ T cells are excluded or absent. In the context of tumor acidity, the role of bicarbonate transporters, key regulators of pH homeostasis, has mostly been neglected so far.

Research Findings

Supported by the ERC consolidator grant ImmunoFit, we recently unveiled that the metabolic editing of the TME via inhibition of a specific bicarbonate transporter in cancer cells represents a novel robust therapeutic strategy. This strategy aims to:

  1. Mitigate the acidity of the TME
  2. Increase the fitness of CD8+ T cells
  3. Render current immunotherapeutic regimens more effective in pancreatic cancer

Proposed Strategy

To progress on the path from ground-breaking research towards innovation, we now propose to de-risk the target by delivering early lead compounds (i.e., blockers) with proven therapeutic efficacy and synergism with immunotherapies in several preclinical tumor models.

Collaboration and Commercialization

These compounds will be valorized for add-on cancer therapy through follow-up R&D collaborations and/or licensing agreements with Pharmaceutical & Biotech companies. This will lead to the commercialization of our sciences and broad societal impact with the deliverable of a brand-new therapeutic approach and combination regimens which are urgently required to tackle tumor resistance or refractoriness vis-à-vis immunotherapies.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-9-2022
Einddatum29-2-2024
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • VIB VZWpenvoerder

Land(en)

Belgium

Vergelijkbare projecten binnen European Research Council

ERC Proof of...

Actionable metabolite supplements to improve treatment response in pancreatic cancer

The ACT-PC project aims to preclinically validate microbiota-derived metabolites to enhance chemotherapy efficacy and anti-tumor immunity in metastatic pancreatic cancer patients.

€ 150.000
ERC Proof of...

Targeting eicosanoid metabolism to overcome tumor immunosuppression

This project aims to enhance cancer immunotherapy efficacy by targeting HPGDS in tumor-associated macrophages to reshape the immunosuppressive tumor microenvironment and improve patient outcomes.

€ 150.000
ERC Consolid...

Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal Adenocarcinoma

PROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity.

€ 1.999.401
ERC Starting...

Decoding Requirements for Infiltration of T ceLLs into solid tumors

This project aims to enhance T cell infiltration into pancreatic cancer by investigating chemokine regulation and T cell determinants, potentially improving immunotherapy efficacy.

€ 1.521.000
ERC Proof of...

Live biotherapeutics to potentiate cancer immunotherapy

The project aims to enhance immunotherapy efficacy by using engineered live biotherapeutics to normalize tumor stiffness and improve blood flow in colorectal and breast cancer models.

€ 150.000

Vergelijkbare projecten uit andere regelingen

Mkb-innovati...

Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker

De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.

€ 20.000
Mkb-innovati...

PRO CellecT

Pan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren.

€ 20.000
EIC Accelerator

FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY

MYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes.

€ 2.494.504
EIC Accelerator

Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering

The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.

€ 2.434.790
EIC Pathfinder

A minimally Invasive surgical platform aGainst paNcreatIc and biliary Tract cancErs using cold atmospheric PLASMA

This project aims to develop a novel cold atmospheric pressure plasma system for minimally invasive treatment of pancreatic and biliary tract cancers, integrating advanced modeling and in-vivo testing.

€ 2.792.500